These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 38416633)
61. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577 [TBL] [Abstract][Full Text] [Related]
62. Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Marra AM; Benjamin N; Eichstaedt C; Salzano A; Arcopinto M; Gargani L; D Alto M; Argiento P; Falsetti L; Di Giosia P; Isidori AM; Ferrara F; Bossone E; Cittadini A; Grünig E Pharmacol Res; 2016 Dec; 114():103-109. PubMed ID: 27771466 [TBL] [Abstract][Full Text] [Related]
63. Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials. Rose JA; Cleveland JM; Rao Y; Minai OA; Tonelli AR Chest; 2016 May; 149(5):1234-44. PubMed ID: 26836910 [TBL] [Abstract][Full Text] [Related]
65. Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here? Macchia A; Mariani J; Comignani PD; Tognoni G Rev Recent Clin Trials; 2011 Sep; 6(3):228-34. PubMed ID: 21682677 [TBL] [Abstract][Full Text] [Related]
74. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Kabunga P; Coghlan G Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488 [TBL] [Abstract][Full Text] [Related]
75. Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension. Skoro-Sajer N; Lang I Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1391-9. PubMed ID: 25363827 [TBL] [Abstract][Full Text] [Related]
76. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis]. Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085 [No Abstract] [Full Text] [Related]
77. Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy? Steele P; Strange G; Wlodarczyk J; Dalton B; Stewart S; Gabbay E; Keogh A BMC Cardiovasc Disord; 2010 Feb; 10():9. PubMed ID: 20170553 [TBL] [Abstract][Full Text] [Related]
78. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. De Wet CJ; Affleck DG; Jacobsohn E; Avidan MS; Tymkew H; Hill LL; Zanaboni PB; Moazami N; Smith JR J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1058-67. PubMed ID: 15052203 [TBL] [Abstract][Full Text] [Related]
79. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension. Budev MM; Minai OA; Arroliga AC Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531 [TBL] [Abstract][Full Text] [Related]
80. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Dranitsaris G; Mehta S Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]